In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials

A multicentre international trial

R. N. Jones, R. S. Hareb, F. J. Sabatelli, K. Aldridge, P. Della-Latta, M. J. Ferraro, Richard V. Goering, J. Hindkler, D. Bruckner, M. Jacobs, R. Jones, D. Low, A. Medeiros, J. Boyce, B. Murray, F. Baquero, D. Costa, N. Frimodt-Møller, H. Goossens, D. Graninger & 18 others S. Gudmundsson, D. Gur, P. Huovinen, M. Kettner, E. Keuleyen, K. Klugman, R. Le Clercq, J. Patzer, G. Petrikkos, E. Lingaas, C. Nord, G. Reshedko, L. Stratchounski, J. Schindler, G. C. Schito, M. E. Jones, B. Wiedemann, R. Wise

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The antimicrobial activity of evernimicin (formerly SCH 27899), a novel oligosaccharide antimicrobial of the everninomicin class, was evaluated against four groups of Gram-positive pathogens: (i) Streptococcus pneumoniae (n = 1452); (ii) methicillin- or oxacillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (MR-CoNS; n = 1427); (iii) enterococci (n = 1517); and (iv) non-pneumococcal streptococci (n = 1388), using the Etest method at each study centre throughout Eastern and Western Europe, Scandinavia, South Africa, Turkey and North America. Comparative MICs were determined for a variety of reference compounds, including vancomycin, quinupristin/dalfopristin, chloramphenicol, penicillin, ampicillin, oxacillin, ceftriaxone and ciprofloxacin. Evernimicin was highly active against all strains tested, with MIC90 values ≤1.0 mg/L, ranging from 0.047 mg/L against S. pneumoniae to 1.0 mg/L against MRSA/MR-CoNS and enterococci. Compared with the reference agents, the MIC90 of evernimicin were lower against all species. Against MRSA and MR-CoNS the MIC90s of evernimicin, quinupristin/dalfopristin and vancomycin (the three most active agents) were 1.0, 1.5 and 3.0 mg/L, respectively. Against all species tested, the relative activities and spectra of these agents were: evernimicin > vancomycin > quinupristin/dalfopristin. The Etest proved to be reliable and reproducible, despite occasional interpretive difficulties caused by observer inexperience. Quality control results were excellent among the 33 participant sites. The results of this in vitro, multicentre, multinational study demonstrate that evernimicin possesses high antimicrobial activity against Gram-positive organisms that compares favourably with established antibacterial treatments and newer agents such as quinupristin/dalfopristin. Further clinical investigations of everninomicin class compounds appear warranted.

Original languageEnglish
Pages (from-to)15-25
Number of pages11
JournalJournal of Antimicrobial Chemotherapy
Volume47
Issue number1
StatePublished - 2001

Fingerprint

Oligosaccharides
Multicenter Studies
Oxacillin
Methicillin
Vancomycin
Disk Diffusion Antimicrobial Tests
Staphylococcus aureus
Enterococcus
Streptococcus pneumoniae
Scandinavian and Nordic Countries
evernimicin
In Vitro Techniques
Eastern Europe
Ceftriaxone
South America
Coagulase
Chloramphenicol
Ampicillin
Ciprofloxacin
North America

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Microbiology

Cite this

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials : A multicentre international trial. / Jones, R. N.; Hareb, R. S.; Sabatelli, F. J.; Aldridge, K.; Della-Latta, P.; Ferraro, M. J.; Goering, Richard V.; Hindkler, J.; Bruckner, D.; Jacobs, M.; Jones, R.; Low, D.; Medeiros, A.; Boyce, J.; Murray, B.; Baquero, F.; Costa, D.; Frimodt-Møller, N.; Goossens, H.; Graninger, D.; Gudmundsson, S.; Gur, D.; Huovinen, P.; Kettner, M.; Keuleyen, E.; Klugman, K.; Le Clercq, R.; Patzer, J.; Petrikkos, G.; Lingaas, E.; Nord, C.; Reshedko, G.; Stratchounski, L.; Schindler, J.; Schito, G. C.; Jones, M. E.; Wiedemann, B.; Wise, R.

In: Journal of Antimicrobial Chemotherapy, Vol. 47, No. 1, 2001, p. 15-25.

Research output: Contribution to journalArticle

Jones, RN, Hareb, RS, Sabatelli, FJ, Aldridge, K, Della-Latta, P, Ferraro, MJ, Goering, RV, Hindkler, J, Bruckner, D, Jacobs, M, Jones, R, Low, D, Medeiros, A, Boyce, J, Murray, B, Baquero, F, Costa, D, Frimodt-Møller, N, Goossens, H, Graninger, D, Gudmundsson, S, Gur, D, Huovinen, P, Kettner, M, Keuleyen, E, Klugman, K, Le Clercq, R, Patzer, J, Petrikkos, G, Lingaas, E, Nord, C, Reshedko, G, Stratchounski, L, Schindler, J, Schito, GC, Jones, ME, Wiedemann, B & Wise, R 2001, 'In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: A multicentre international trial', Journal of Antimicrobial Chemotherapy, vol. 47, no. 1, pp. 15-25.
Jones, R. N. ; Hareb, R. S. ; Sabatelli, F. J. ; Aldridge, K. ; Della-Latta, P. ; Ferraro, M. J. ; Goering, Richard V. ; Hindkler, J. ; Bruckner, D. ; Jacobs, M. ; Jones, R. ; Low, D. ; Medeiros, A. ; Boyce, J. ; Murray, B. ; Baquero, F. ; Costa, D. ; Frimodt-Møller, N. ; Goossens, H. ; Graninger, D. ; Gudmundsson, S. ; Gur, D. ; Huovinen, P. ; Kettner, M. ; Keuleyen, E. ; Klugman, K. ; Le Clercq, R. ; Patzer, J. ; Petrikkos, G. ; Lingaas, E. ; Nord, C. ; Reshedko, G. ; Stratchounski, L. ; Schindler, J. ; Schito, G. C. ; Jones, M. E. ; Wiedemann, B. ; Wise, R. / In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials : A multicentre international trial. In: Journal of Antimicrobial Chemotherapy. 2001 ; Vol. 47, No. 1. pp. 15-25.
@article{f3054a531c624749a131874362cb851f,
title = "In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: A multicentre international trial",
abstract = "The antimicrobial activity of evernimicin (formerly SCH 27899), a novel oligosaccharide antimicrobial of the everninomicin class, was evaluated against four groups of Gram-positive pathogens: (i) Streptococcus pneumoniae (n = 1452); (ii) methicillin- or oxacillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (MR-CoNS; n = 1427); (iii) enterococci (n = 1517); and (iv) non-pneumococcal streptococci (n = 1388), using the Etest method at each study centre throughout Eastern and Western Europe, Scandinavia, South Africa, Turkey and North America. Comparative MICs were determined for a variety of reference compounds, including vancomycin, quinupristin/dalfopristin, chloramphenicol, penicillin, ampicillin, oxacillin, ceftriaxone and ciprofloxacin. Evernimicin was highly active against all strains tested, with MIC90 values ≤1.0 mg/L, ranging from 0.047 mg/L against S. pneumoniae to 1.0 mg/L against MRSA/MR-CoNS and enterococci. Compared with the reference agents, the MIC90 of evernimicin were lower against all species. Against MRSA and MR-CoNS the MIC90s of evernimicin, quinupristin/dalfopristin and vancomycin (the three most active agents) were 1.0, 1.5 and 3.0 mg/L, respectively. Against all species tested, the relative activities and spectra of these agents were: evernimicin > vancomycin > quinupristin/dalfopristin. The Etest proved to be reliable and reproducible, despite occasional interpretive difficulties caused by observer inexperience. Quality control results were excellent among the 33 participant sites. The results of this in vitro, multicentre, multinational study demonstrate that evernimicin possesses high antimicrobial activity against Gram-positive organisms that compares favourably with established antibacterial treatments and newer agents such as quinupristin/dalfopristin. Further clinical investigations of everninomicin class compounds appear warranted.",
author = "Jones, {R. N.} and Hareb, {R. S.} and Sabatelli, {F. J.} and K. Aldridge and P. Della-Latta and Ferraro, {M. J.} and Goering, {Richard V.} and J. Hindkler and D. Bruckner and M. Jacobs and R. Jones and D. Low and A. Medeiros and J. Boyce and B. Murray and F. Baquero and D. Costa and N. Frimodt-M{\o}ller and H. Goossens and D. Graninger and S. Gudmundsson and D. Gur and P. Huovinen and M. Kettner and E. Keuleyen and K. Klugman and {Le Clercq}, R. and J. Patzer and G. Petrikkos and E. Lingaas and C. Nord and G. Reshedko and L. Stratchounski and J. Schindler and Schito, {G. C.} and Jones, {M. E.} and B. Wiedemann and R. Wise",
year = "2001",
language = "English",
volume = "47",
pages = "15--25",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials

T2 - A multicentre international trial

AU - Jones, R. N.

AU - Hareb, R. S.

AU - Sabatelli, F. J.

AU - Aldridge, K.

AU - Della-Latta, P.

AU - Ferraro, M. J.

AU - Goering, Richard V.

AU - Hindkler, J.

AU - Bruckner, D.

AU - Jacobs, M.

AU - Jones, R.

AU - Low, D.

AU - Medeiros, A.

AU - Boyce, J.

AU - Murray, B.

AU - Baquero, F.

AU - Costa, D.

AU - Frimodt-Møller, N.

AU - Goossens, H.

AU - Graninger, D.

AU - Gudmundsson, S.

AU - Gur, D.

AU - Huovinen, P.

AU - Kettner, M.

AU - Keuleyen, E.

AU - Klugman, K.

AU - Le Clercq, R.

AU - Patzer, J.

AU - Petrikkos, G.

AU - Lingaas, E.

AU - Nord, C.

AU - Reshedko, G.

AU - Stratchounski, L.

AU - Schindler, J.

AU - Schito, G. C.

AU - Jones, M. E.

AU - Wiedemann, B.

AU - Wise, R.

PY - 2001

Y1 - 2001

N2 - The antimicrobial activity of evernimicin (formerly SCH 27899), a novel oligosaccharide antimicrobial of the everninomicin class, was evaluated against four groups of Gram-positive pathogens: (i) Streptococcus pneumoniae (n = 1452); (ii) methicillin- or oxacillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (MR-CoNS; n = 1427); (iii) enterococci (n = 1517); and (iv) non-pneumococcal streptococci (n = 1388), using the Etest method at each study centre throughout Eastern and Western Europe, Scandinavia, South Africa, Turkey and North America. Comparative MICs were determined for a variety of reference compounds, including vancomycin, quinupristin/dalfopristin, chloramphenicol, penicillin, ampicillin, oxacillin, ceftriaxone and ciprofloxacin. Evernimicin was highly active against all strains tested, with MIC90 values ≤1.0 mg/L, ranging from 0.047 mg/L against S. pneumoniae to 1.0 mg/L against MRSA/MR-CoNS and enterococci. Compared with the reference agents, the MIC90 of evernimicin were lower against all species. Against MRSA and MR-CoNS the MIC90s of evernimicin, quinupristin/dalfopristin and vancomycin (the three most active agents) were 1.0, 1.5 and 3.0 mg/L, respectively. Against all species tested, the relative activities and spectra of these agents were: evernimicin > vancomycin > quinupristin/dalfopristin. The Etest proved to be reliable and reproducible, despite occasional interpretive difficulties caused by observer inexperience. Quality control results were excellent among the 33 participant sites. The results of this in vitro, multicentre, multinational study demonstrate that evernimicin possesses high antimicrobial activity against Gram-positive organisms that compares favourably with established antibacterial treatments and newer agents such as quinupristin/dalfopristin. Further clinical investigations of everninomicin class compounds appear warranted.

AB - The antimicrobial activity of evernimicin (formerly SCH 27899), a novel oligosaccharide antimicrobial of the everninomicin class, was evaluated against four groups of Gram-positive pathogens: (i) Streptococcus pneumoniae (n = 1452); (ii) methicillin- or oxacillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (MR-CoNS; n = 1427); (iii) enterococci (n = 1517); and (iv) non-pneumococcal streptococci (n = 1388), using the Etest method at each study centre throughout Eastern and Western Europe, Scandinavia, South Africa, Turkey and North America. Comparative MICs were determined for a variety of reference compounds, including vancomycin, quinupristin/dalfopristin, chloramphenicol, penicillin, ampicillin, oxacillin, ceftriaxone and ciprofloxacin. Evernimicin was highly active against all strains tested, with MIC90 values ≤1.0 mg/L, ranging from 0.047 mg/L against S. pneumoniae to 1.0 mg/L against MRSA/MR-CoNS and enterococci. Compared with the reference agents, the MIC90 of evernimicin were lower against all species. Against MRSA and MR-CoNS the MIC90s of evernimicin, quinupristin/dalfopristin and vancomycin (the three most active agents) were 1.0, 1.5 and 3.0 mg/L, respectively. Against all species tested, the relative activities and spectra of these agents were: evernimicin > vancomycin > quinupristin/dalfopristin. The Etest proved to be reliable and reproducible, despite occasional interpretive difficulties caused by observer inexperience. Quality control results were excellent among the 33 participant sites. The results of this in vitro, multicentre, multinational study demonstrate that evernimicin possesses high antimicrobial activity against Gram-positive organisms that compares favourably with established antibacterial treatments and newer agents such as quinupristin/dalfopristin. Further clinical investigations of everninomicin class compounds appear warranted.

UR - http://www.scopus.com/inward/record.url?scp=0035185995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035185995&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 15

EP - 25

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -